製品別（アッセイ＆試薬、機器、ソフトウェア）、疾患タイプ別（肝炎、ヒト免疫不全ウイルス、インフルエンザ、その他）、技術別（免疫診断学、臨床微生物学、ポリメラーゼ連鎖反応、次世代シーケンシング、その他）、地域別の感染症診断市場 2030年までの世界予測

Infectious Disease Diagnostics Market based on by Product (Assays & Reagents, Instruments, and Software), Disease Type (Hepatitis, Human Immunodeficiency Virus, Influenza, and Others), and Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Next Generation Sequencing, and Others),Regional Outlook Global Forecast up to 2030

効率的な治療と管理のためには、結核、HIV/AIDS、肝炎、性感染症、呼吸器感染症などの疾患は正確で迅速な診断が必要である。これらの疾患の早期発見は、これらの感染症のサーベイランスにおいて極めて重要であり... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
IHR Insights アイエイチアールインサイト	2024年1月10日	US$4,500 シングルユーザライセンスライセンス・価格情報注文方法はこちら	108	英語

目次
図表リスト

サマリー

効率的な治療と管理のためには、結核、HIV/AIDS、肝炎、性感染症、呼吸器感染症などの疾患は正確で迅速な診断が必要である。これらの疾患の早期発見は、これらの感染症のサーベイランスにおいて極めて重要であり、この分野の市場成長を後押ししている。
不十分な診療報酬は業界の拡大を妨げる重要な問題である。MedPAC（Medicare Payment Advisory Commission：医療保険支払い諮問委員会）によれば、医療検査は過去40年間で40％の償還金減少に見舞われている。この減少は、医療機関の余分な経済的懸念と同様に、臨床検査室における革新的な診断方法の使用を妨げる大きな要因となっている。

ページTOPに戻る

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Product: Market Size & Analysis
5.1. Overview
5.2. Assays & Reagents
5.3. Instruments
5.4. Software
6. Disease Type: Market Size & Analysis
6.1. Overview
6.2. Hepatitis
6.3. Human Immunodeficiency Virus
6.4. Influenza
6.5. Others
7. Technology: Market Size & Analysis
7.1. Overview
7.2. Immunodiagnostics
7.3. Clinical Microbiology
7.4. Polymerase Chain Reaction
7.5. Next Generation Sequencing
7.6. Others
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. AMGEN, INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ASTRAZENECA, PLC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. BAYER AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. BRISTOL-MYERS SQUIBB COMPANY
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. ELI LILY AND COMPANY
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.)
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. PFIZER, INC.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. MERCK KGAA
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. NOVARTIS AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion
12. Annexure

ページTOPに戻る

図表リスト

TABLE 1. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR ASSAYS & REAGENTS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR SOFTWARE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 6. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR HEPATITIS, 2021-2030 (USD BILLION)
TABLE 7. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR HUMAN IMMUNODEFICIENCY VIRUS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 11. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR IMMUNODIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR CLINICAL MICROBIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR POLYMERASE CHAIN REACTION, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR NEXT GENERATION SEQUENCING, 2021-2030 (USD BILLION)
TABLE 15. INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 20. U.S INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. U.S INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 23. CANADA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 24. CANADA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 25. CANADA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 26. MEXICO INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. MEXICO INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 28. MEXICO INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 29. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 30. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 33. GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 34. GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 35. GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 36. U.K INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 37. U.K INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 38. U.K INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 39. FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 40. FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 41. FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 42. ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 43. ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 44. ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 45. SPAIN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. SPAIN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 47. SPAIN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 48. ROE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ROE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 50. ROE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 55. CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 57. CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 58. INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 59. INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 60. INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 61. JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 62. JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 63. JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 82. UAE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 83. UAE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 84. UAE INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION)
TABLE 88. AMGEN, INC. : FINANCIALS
TABLE 89. AMGEN, INC. : PRODUCTS & SERVICES
TABLE 90. AMGEN, INC. : RECENT DEVELOPMENTS
TABLE 91. ASTRAZENECA, PLC: FINANCIALS
TABLE 92. ASTRAZENECA, PLC: PRODUCTS & SERVICES
TABLE 93. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
TABLE 94. BAYER AG: FINANCIALS
TABLE 95. BAYER AG: PRODUCTS & SERVICES
TABLE 96. BAYER AG: RECENT DEVELOPMENTS
TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 100. ELI LILY AND COMPANY: FINANCIALS
TABLE 101. ELI LILY AND COMPANY: PRODUCTS & SERVICES
TABLE 102. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
TABLE 103. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
TABLE 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
TABLE 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
TABLE 106. PFIZER, INC. : FINANCIALS
TABLE 107. PFIZER, INC. : PRODUCTS & SERVICES
TABLE 108. PFIZER, INC. : DEVELOPMENTS
TABLE 109. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
TABLE 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
TABLE 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
TABLE 112. MERCK KGAA: FINANCIALS
TABLE 113. MERCK KGAA: PRODUCTS & SERVICES
TABLE 114. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 115. NOVARTIS AG: FINANCIALS
TABLE 116. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 117. NOVARTIS AG: RECENT DEVELOPMENTS

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

For efficient treatment and management, diseases such as TB, HIV/AIDS, hepatitis, sexually transmitted infections, and respiratory infections require an accurate and prompt diagnosis. Early detection of these disorders is critical in the surveillance of these infectious diseases, boosting market growth in this field.
Inadequate reimbursements are a key problem impeding industry expansion. Medical testing has suffered a 40% decrease in reimbursement over the previous 40 years, according to MedPAC (Medicare Payment Advisory Commission). This reduction, as well as extra economic concerns among healthcare organisations, are significant impediments to the use of innovative diagnostic procedures in clinical laboratories.

ページTOPに戻る

List of Tables/Graphs

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

IHR Insights社の医療分野での最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート

よくあるご質問

IHR Insights社はどのような調査会社ですか?

IHR InsightsはICT、化学品、ヘルスケア、半導体など、世界の幅広い分野を対象に調査し、専門的な知識を基に市場調査報告書を出版しています。主な調査分野 ◇ICT ◇化学品、材料、... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

IHR Insights社の医療分野での最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート

よくあるご質問

IHR Insights社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?